Andrew Beck

Andrew Beck possesses extensive experience in the biopharmaceutical sector, currently serving as Scientist II at Enlaza Therapeutics since September 2022. Previously, Andrew held positions as Scientist I at Ambrx, Senior Associate Scientist at Celgene, and Research Associate at Ambrx, focusing on the purification and analysis of therapeutic proteins, including monoclonal antibodies and antibody-drug conjugates. Earlier in the career, Andrew worked as a Biochemist at BD Biosciences, specializing in custom conjugations, and briefly contributed to quality control in reagent preparation at Quidel. Andrew earned a degree in Biochemistry from UC San Diego in 2007.